GlassScriptPhysician profile
Greta S Slappy
NPI 1447644265
$1,928.05
in general payments reported to CMS, 2019-2025
27 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $377 · 2023: $508 · 2024: $394 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272.66 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Cardiovascular Systems INC. | $209.16 | 2021-2023 | Diamondback Peripheral |
| Novo Nordisk INC | $168.32 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bard Peripheral Vascular, INC. | $133.12 | 2023-2025 | Lifestent Solo Vascular Stent, Rotarexs 6 F X 135 Cm |
| Organogenesis INC. | $121.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $102.72 | 2021-2023 | Xarelto |
| Abbvie INC. | $96.25 | 2025 | |
| Abbott Laboratories | $90.96 | 2023 | Diamondback Peripheral |
| Sumitomo Pharma America, INC. | $84.24 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $73.93 | 2023-2024 | |
| Shield Therapeutics INC | $47.44 | 2024 | |
| Paratek Pharmaceuticals, INC. | $44.50 | 2023-2025 | Nuzyra, Xhance |
| Inari Medical, INC. | $44.38 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lemaitre Vascular, INC. | $42.51 | 2022 | |
| Glaxosmithkline, LLC. | $42.37 | 2025 | Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.02 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $40.73 | 2025 | |
| Astellas Pharma US INC | $37.45 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $36.25 | 2023 | Nuedexta |
| Astrazeneca Pharmaceuticals LP | $35.53 | 2024 | Farxiga, Airsupra |
| Medtronic, INC. | $35.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.69 | 2021 | |
| Dexcom, INC. | $24.84 | 2024 | Dexcom G6 Transmitter |
| Cordis US Corp. | $24.69 | 2021 | |
| Amgen INC. | $15.26 | 2025 | Repatha |
| Integra Lifesciences Corporation | $14.61 | 2022 | |
| Boston Scientific Corporation | $14.48 | 2023 | Varithena Administration Pack |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greta Slappy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.